{
  "ticker": "ACQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968360",
  "id": "02968360",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250710",
  "time": "1841",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lpjb023wqjbm.pdf",
  "summary": "### Key Material Information (Investment Update \u2013 June 2025)  \n\n- **NTA per Share (unaudited)**:  \n  - Before taxes: **$1.1143**  \n  - After taxes (excl. unrealised gains tax): **$1.1230**  \n  - After taxes (incl. unrealised gains tax): **$1.1091**  \n\n- **Share Price & Dividend**:  \n  - **Share Price**: $0.76 (trading at **~31.8% discount to post-tax NTA**)  \n  - **Dividend Yield**: 7.2% (5.5c dividends paid over past 12 months).  \n\n- **Portfolio Performance (vs. Benchmark)**:  \n  - **1-month return**: +4.6% (outperformed S&P/ASX Small Ords by **3.8%**)  \n  - **Top contributors**: Amplia Therapeutics (+278.8% on clinical trial news), ZIP Co (+60.9% on upgraded EBITDA guidance).  \n  - **Top detractor**: Golden Horse Minerals (-10.1% due to capital raising).  \n\n- **Portfolio Composition**:  \n  - **21.1% unlisted**, **71.1% listed**, **7.8% cash**.  \n  - **Top 10 holdings**: 28.8% of portfolio (Aroa Biosurgery, Superloop, Meeka Metals leading).  \n\n- **Dividend Policy**: Targets **5% of post-tax NTA annually**, with potential special dividends for excess franking credits.  \n\n*No material capital markets actions (e.g., raising, trading halt) identified.*",
  "usage": {
    "prompt_tokens": 2592,
    "completion_tokens": 349,
    "total_tokens": 2941,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-10T09:03:23.992321"
}